

## DAFTAR PUSTAKA

- Abdullahi W, Tripathi D, Ronaldson PT, 2018. Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection. *American Journal of Physiology-Cell Physiology* 315(3):343–356. Available at: <https://doi.org/10.1152/ajpcell.00095.2018>
- Van Aken BC, et al, 2025. A cross-sectional study on the association between executive functions and social disabilities in people with a psychotic disorder. *Schizophrenia Research: Cognition* 40:100349. Available at: <https://doi.org/10.1016/j.scog.2025.100349>
- Alfimova M, Plakunova VV, Golimbet VE, 2024. Learning Slope and Position Effects in Rey Auditory Verbal Learning Test: Diagnostic Value in Schizophrenia. *Clinical Psychology and Special Education* 13(3):186–204. Available at: <https://doi.org/10.17759/cpse.2024130309>
- Antoniades M, et al, 2018. Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis. *Neuroscience & Biobehavioral Reviews* 86:166–175. Available at: <https://doi.org/10.1016/j.neubiorev.2017.12.001>
- Arnsten AFT, 2015. Stress weakens prefrontal networks: molecular insults to higher cognition. *Nature Neuroscience* 18(10):1376–1385. Available at: <https://doi.org/10.1038/nn.4087>
- Ashendorf L, et al, 2008. Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. *Archives of Clinical Neuropsychology* 23(2):129–137. Available at: <https://doi.org/10.1016/j.acn.2007.11.005>
- Auton A, et al, 2015. A global reference for human genetic variation. *Nature* 526(7571):68–74. Available at: <https://doi.org/10.1038/nature15393>
- Avram M, et al, 2019. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. *Brain* 142(6):1813–1826. Available at: <https://doi.org/10.1093/brain/awz093>

- Avram M, et al, 2020. Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia. *Brain* 143(11):3495–3505. Available at: <https://doi.org/10.1093/brain/awaa296>
- Baddeley A, 2012. Working Memory: Theories, Models, and Controversies. *Annual Review of Psychology* 63(1):1–29. Available at: <https://doi.org/10.1146/annurev-psych-120710-100422>
- Barch D, 2019. Mechanisms underlying cognitive impairment in schizophrenia and implications for treatment. *Behavioral Neurosciences* 44:1–21. Available at: [https://doi.org/10.1007/7854\\_2019\\_97](https://doi.org/10.1007/7854_2019_97)
- Bellucco F, et al, 2014. PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia. *PLoS ONE* 9(2). Available at: <https://doi.org/10.1371/journal.pone.0087686>
- Białoń M, Wąsik A, 2022. Advantages and Limitations of Animal Schizophrenia Models. *International Journal of Molecular Sciences* 23(11):5968. Available at: <https://doi.org/10.3390/ijms23115968>
- Bocharova AV, et al, 2017. Association Study of Genetic Markers of Schizophrenia and Its Cognitive Endophenotypes. Available at: <https://doi.org/10.1134/S1022795417010033>
- Borna A, et al, 2016. An Overview of the Factors Affecting the Results of Rey Auditory Verbal Learning Test. 5:282–289
- Brébion G, et al, 2004. Semantic Organization and Verbal Memory Efficiency in Patients with Schizophrenia. *Neuropsychology* 18(2):378–383. Available at: <https://doi.org/10.1037/0894-4105.18.2.378>
- Brugger SP, Howes OD, 2017. Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia. *JAMA Psychiatry* 74(11):1104. Available at: <https://doi.org/10.1001/jamapsychiatry.2017.2663>
- Bushman BJ, Anderson CA, 2002. Violent Video Games and Hostile Expectations: A Test of the General Aggression Model. *Personality and*

Social Psychology Bulletin 28(12):1679–1686. Available at:  
<https://doi.org/10.1177/014616702237649>

Cappelletti P, et al, 2018. Proline oxidase controls proline, glutamate, and glutamine cellular concentrations in a U87 glioblastoma cell line. PLoS One 13(4):1–20. Available at: <https://doi.org/10.1371/journal.pone.0196283>

Carvalho GA, et al, 2025. Neurobiology of L-proline: From molecules to behavior. Neuroscience 568:116–129. Available at:  
<https://doi.org/10.1016/j.neuroscience.2025.01.036>

Castle D, Buckley PF, 2015. Schizophrenia, Oxford Psychiatry Library 128.

Charlson FJ, et al, 2018. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin 44(6):1195–1203. Available at:  
<https://doi.org/10.1093/schbul/sby058>

Cheng W, et al, 2021. Genetic Association between Schizophrenia and Cortical Brain Surface Area and Thickness. JAMA Psychiatry 78(9):1020–1030. Available at: <https://doi.org/10.1001/jamapsychiatry.2021.1435>

Chiu PW, et al, 2018. In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study. Schizophrenia Research 193:295–303. Available at:  
<https://doi.org/10.1016/j.schres.2017.07.021>

Ciolek CH, Lee SY, 2020. Cognitive Issues in the Older Adult, in Guccione Geriatric Physical Therapy. 4th edn. Elsevier 425–452. Available at:  
<https://doi.org/10.1016/B978-0-323-60912-8.00019-1>

Cippitelli A, et al, 2022. PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. Neuropharmacology 211:109045. Available at:  
<https://doi.org/10.1016/j.neuropharm.2022.109045>

Clelland CL, et al, 2012. and a Measure of Clinical Outcome, 131:139–145. Available at: <https://doi.org/10.1016/j.schres.2011.05.006.Evidence>

- Clelland CL, et al, 2016. Evidence that COMT genotype and proline interact on negative-symptom outcomes in schizophrenia and bipolar disorder. *Translational Psychiatry* 6(9). Available at: <https://doi.org/10.1038/TP.2016.157>
- Clinic M, 2011 *Encyclopedia of Clinical Neuropsychology*, *Encyclopedia of Clinical Neuropsychology*. Edited by J.S. Kreutzer, J. DeLuca, and B. Caplan. New York, NY: Springer New York. Available at: <https://doi.org/10.1007/978-0-387-79948-3>
- Correia S, et al, 2015. Lowering the floor on trail making test Part B: Psychometric evidence for a new scoring metric. *Archives of Clinical Neuropsychology* 30(7):643–656. Available at: <https://doi.org/10.1093/arclin/acv040>
- Crabtree GW, et al, 2016. Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade. *Cell Reports* 17(2):570–582. Available at: <https://doi.org/10.1016/j.celrep.2016.09.029>
- Damanik R, Effendy E, Surya HM, 2020. The relation of gene polymorphism interferon gamma+874 a/t and schizophrenia occurred in batak ethnicity. *Open Access Macedonian Journal of Medical Sciences* 8(A):70–75. Available at: <https://doi.org/10.3889/oamjms.2020.3975>
- DeLuca GC, et al, 2015. Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. *Brain pathology* 25(1):79–98. Available at: <https://doi.org/10.1111/bpa.12220>
- Dhaka N, et al, 2020. Cognitive dysfunctions in patients with bipolar disorder: A comparative study from Western Rajasthan. *Asian Journal of Medical Research* 9(2):1–6. Available at: <https://doi.org/10.47009/ajmr.2020.9.2.PY1>
- Diamond A, 2016. Why improving and assessing executive functions early in life is critical, in *Executive function in preschool-age children: Integrating measurement, neurodevelopment, and translational research*. Washington:

American Psychological Association 11–43. Available at:  
<https://doi.org/10.1037/14797-002>

Dietz AG, Goldman SA, Nedergaard M, 2020. Glial cells in schizophrenia: a unified hypothesis. *The Lancet Psychiatry* 7(3):272–281. Available at:  
[https://doi.org/10.1016/S2215-0366\(19\)30302-5](https://doi.org/10.1016/S2215-0366(19)30302-5)

Dinkes, 2019. Riset Kesehatan Dasar Provinsi Sumatera Barat Tahun 2018, Laporan Riskesdas Nasional 2018

Dito T, Ikrar T, 2014. The Neuroscience of Glutamate. *Medical Journal of Indonesia* 120:55–61

Doyon J, et al, 2018. Current issues related to motor sequence learning in humans. *Current Opinion in Behavioral Sciences* 20:89–97. Available at:  
<https://doi.org/10.1016/j.cobeha.2017.11.012>

Duarte M, et al, 2017. Hyperprolinemia as a clue in the diagnosis of a patient with psychiatric manifestations. *Brain and Development* 39(6):539–541. Available at: <https://doi.org/10.1016/j.braindev.2017.01.008>

Egerton A, et al, 2020. Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. *Schizophrenia Research* 223:59–70. Available at: <https://doi.org/10.1016/j.schres.2020.09.013>.

Elvira SD, Hadisukanto G, 2017. Buku ajar psikiatri. 3rd edn. Jakarta: FKUI

Enwright JF, et al, 2016. Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia. *Neuropsychopharmacology* 41(9):2206–2214. Available at:  
<https://doi.org/10.1038/npp.2016.24>

Erhardt S, et al, 2017. The kynurenine pathway in schizophrenia and bipolar disorder. *Neuropharmacology* 112:297–306. Available at:  
<https://doi.org/10.1016/j.neuropharm.2016.05.020>

Farah FH, 2018. Schizophrenia : An Overview. *Asian Journal of Pharmaceutics* 12(17)

- Fatani BZ, Aldawod RA, Alhawaj FA, 2017. Schizophrenia : Etiology, Pathophysiology and Management : A Review. The Egyptian Journal of Hospital Medicine 69(6):2640–2646. Available at: <https://doi.org/10.12816/0042241>
- Fazio F, et al, 2015. Xanthurenic Acid Activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Scientific Reports 5(November):1–14. Available at: <https://doi.org/10.1038/srep17799>
- Feng T, Tripathi A, Pillai A, 2020. Inflammatory Pathways in Psychiatric Disorders: the Case of Schizophrenia and Depression. Current Behavioral Neuroscience Reports 7(3):128–138. Available at: <https://doi.org/10.1007/s40473-020-00207-4>
- Fichman Y, et al, 2015. Evolution of proline biosynthesis: enzymology, bioinformatics, genetics, and transcriptional regulation. Biological Reviews 90(4):1065–1099. Available at: <https://doi.org/10.1111/brv.12146>
- Filipčević IŠ, Filipčević I, 2018. Schizophrenia and physical comorbidity. Psychiatria Danubina 30(October):S152–S157
- Fricke-Galindo I, et al, 2022. Impact of COMT, PRODH and DISC1 Genetic Variants on Cognitive Performance of Patients with Schizophrenia. Archives of Medical Research 53(4):388–398. Available at: <https://doi.org/10.1016/j.arcmed.2022.03.00>
- Friederici AD, 2015. White-matter pathways for speech and language processing. in 177–186. Available at: <https://doi.org/10.1016/B978-0-444-62630-1.00010-X>
- Fujigaki H, et al, 2019. Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia. Neurochemistry International 125:1–6. Available at: <https://doi.org/10.1016/j.neuint.2019.02.001>

- García-Gutiérrez MS, et al, 2020. Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality. *Frontiers in Psychiatry* 11:1–14. Available at: <https://doi.org/10.3389/fpsyt.2020.00432>
- Geljic M, et al, 2025. Visual integration deficits associated with psychosis are independent of diagnosis. *Schizophrenia* 11(1):58. Available at: <https://doi.org/10.1038/s41537-025-00606-0>
- Georgiou R, Lamnisos D, Giannakou K, 2021. Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review. *Frontiers in Psychiatry* 12. Available at: <https://doi.org/10.3389/fpsyt.2021.779607>
- Ghasemvand F, et al, 2015. Relationship between polymorphisms in the proline dehydrogenase gene and schizophrenia risk. *Genetics and Molecular Research* 14(4):11681–11691. Available at: <https://doi.org/10.4238/2015.October.2.1>
- Guedes de Pinho LM, Pereira AM, de S, Chaves CMCB, 2018. Quality of life in schizophrenic patients: the influence of sociodemographic and clinical characteristics and satisfaction with social support. *Trends in Psychiatry and Psychotherapy* 40(3):202–209. Available at: <https://doi.org/10.1590/2237-6089-2017-0002>
- Guo X, et al, 2018. Proline dehydrogenase gene (PRODH) polymorphisms and schizophrenia susceptibility: a meta-analysis. *Metabolic Brain Disease* 33(1):89–97. Available at: <https://doi.org/10.1007/s11011-017-0128-8>
- Hale JB, Hoepfner JAB, Fiorello CA, 2002. Analyzing Digit Span Components for Assessment of Attention Processes. *Journal of Psychoeducational Assessment* 20(2):128–143. Available at: <https://doi.org/10.1177/07342829020200020>
- Harvey PD, 2019. Domains of cognition and their assessment. *Dialogues in Clinical Neuroscience* 21(3):227–237. Available at: <https://doi.org/10.31887/DCNS.2019.21.3/pharvey>

Harvey PD, et al, 2022. Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. *Schizophrenia Research: Cognition* 29:100249. Available at: <https://doi.org/10.1016/j.scog.2022.100249>

Hasse-Sousa M, et al, 2023. The role of semantic clustering in the relationship between verbal memory and psychosocial functioning in schizophrenia and bipolar disorder: Possible distinct cognitive pathway compared to healthy controls. *Journal of Affective Disorders* 320: 330–339. Available at: <https://doi.org/10.1016/j.jad.2022.09.077>

Henriksen MG, Nordgaard J, Jansson LB, 2017. Genetics of Schizophrenia: Overview of Methods, Findings and Limitations. *Frontiers in Human Neuroscience* 11. Available at: <https://doi.org/10.3389/fnhum.2017.00322>

Hickok G, 2019. The architecture of speech production and the role of the frontal cortex in language. *Neuron* 105(2):236–247

Honors S, et al, 2011. *Encyclopedia of Clinical Neuropsychology*, Encyclopedia of Clinical Neuropsychology. Edited by J.S. Kreutzer, J. DeLuca, and B. Caplan. New York, NY: Springer New York. Available at: <https://doi.org/10.1007/978-0-387-79948-3>

Huang X, et al, 2020. Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia. *Neuropsychiatric Disease and Treatment* 16:263–271. Available at: <https://doi.org/10.2147/NDT.S239763>

Ivanova SA, et al, 2014. Glutamate Concentration in the Serum of Patients with Schizophrenia. *Procedia Chemistry* 10:80–85. Available at: <https://doi.org/10.1016/j.proche.2014.10.015>

Javitt DC, et al, 2012. Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. *Schizophrenia Bulletin* 38(5):958–966. Available at: <https://doi.org/10.1093/schbul/sbs069>

- Jun R, et al, 2022. Dysbindin-1, BDNF, and GABAergic Transmission in Schizophrenia. *Frontiers in psychiatry* 13:1–7. Available at: <https://doi.org/10.3389/fpsyt.2022.876749>
- Kahn RS, et al, 2015. Schizophrenia. *Nature Reviews Disease Primers* 1. Available at: <https://doi.org/10.1038/nrdp.2015.67>
- Karczewski KJ, et al, 2020. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581(7809):434–443. Available at: <https://doi.org/10.1038/s41586-020-2308-7>
- Karimian SS, Akbari MT, 2018. The Association of V427M Missense Mutation of the PRODH Gene with Schizophrenia in the Iranian Patients. *Journal of Human Genetics and Genomics In Press(In Press):0–4*. Available at: <https://doi.org/10.5812/jhgg.83501>
- KEMENKES, 2018. Riset Kesehatan Dasar (RISKESDAS). Jakarta
- Kemenkes RI, 2019. Profil Kesehatan Indonesia 2018 [Indonesia Health Profile 2018]
- Kim JH, et al, 2012. Lack of association between proline dehydrogenase (oxidase) 1 polymorphisms and schizophrenia in a Korean population. *Psychiatric genetics* 22(3):153–154. Available at: <https://doi.org/10.1097/ypg.0b013e32834c0c61>
- Kindler J, et al, 2020. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. *Molecular Psychiatry* 25(11):2860–2872. Available at: <https://doi.org/10.1038/s41380-019-0401-9>
- Kruse AO, Bustillo JR, 2022. Glutamatergic dysfunction in Schizophrenia. *Translational Psychiatry* 12(1). Available at: <https://doi.org/10.1038/s41398-022-02253-w>
- Kushwaha A, et al, 2024. Assessment of memory deficits in psychiatric disorders: A systematic literature review. Available at: <https://doi.org/10.13140/RG.2.2.29959.82084>

De la Serna E, et al, 2023. Relationship between cognition and age at onset of first-episode psychosis: comparative study between adolescents, young adults, and adults. *European Child & Adolescent Psychiatry* 32(4):639–649. Available at: <https://doi.org/10.1007/s00787-021-01901-8>

Laming D, 2019. Sensory memory: Part 1. *Quarterly Journal of Experimental Psychology* 73(3): 584–600

Leavitt V, Cirillo M, Cohen J, 2023. Hippocampal contributions to verbal learning and memory in psychosis: A multi-cohort meta-analysis. *Neuropsychology* 37(4):389–400


Lesh TA, 2020. Glutamate and dopamine dysfunction in schizophrenia and their association with cognitive impairments. *Neuropsychopharmacology* 45(1):145–155

Li CT, Yang KC, Lin WC, 2019. Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies. *Frontiers in Psychiatry* 9. Available at: <https://doi.org/10.3389/fpsyt.2018.00767>

Li T, et al, 2008. PRODH gene is associated with executive function in schizophrenic families. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 147B(5):654–657. Available at: <https://doi.org/10.1002/ajmg.b.30648>

Li W, Yue L, Xiao S, 2025. Demographic, biochemical, clinical, and cognitive symptom differences between smokers and non-smokers in Chinese older male patients with chronic schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience* 275(1):193–199. Available at: <https://doi.org/10.1007/s00406-024-01762-7>

Li X, Zhou W, Yi Z, 2022. A glimpse of gender differences in schizophrenia. *General Psychiatry* 35(4):100823. Available at: <https://doi.org/10.1136/gpsych-2022-100823>



Linderholm K, 2016. Increased levels of kynurenic acid in the cerebrospinal fluid of patients with schizophrenia. *Schizophrenia Bulletin* 42(3):648–657. Available at: <https://doi.org/10.1093/schbul/sbv205>

Liu Y, et al, 2019. GABA releases from parvalbumin-expressing and unspecified GABAergic neurons onto CA1 pyramidal cells are differentially modulated by presynaptic GABA B receptors in mouse hippocampus. *Biochemical and Biophysical Research Communications* 520(2):449–452. Available at: <https://doi.org/10.1016/j.bbrc.2019.10.044>

Llinàs-Reglà J, et al, 2017. The Trail Making Test: Association With Other Neuropsychological Measures and Normative Values for Adults Aged 55 Years and Older From a Spanish-Speaking Population-Based Sample. *Assessment* 24(2):183–196. Available at: <https://doi.org/10.1177/1073191115602552>

Lonie JA, 2019. Predicting dementia using verbal fluency performance: Age, education, and gender-related differences. *Journal of Alzheimers Disease* 70(1):61–70

Lovelace MD, et al, 2016. Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. *Frontiers in Immunology* 7. Available at: <https://doi.org/10.3389/fimmu.2016.00246>

Luvsannyam E, et al, 2022. Neurobiology of Schizophrenia: A Comprehensive Review. *Cureus* [Preprint]. Available at: <https://doi.org/10.7759/cureus.23959>

Madeira C, Alheira FV, Calcia MA, Silva, Thuany CS, et al, 2018. Blood Levels of Glutamate and Glutamine in Recent Onset and Chronic Schizophrenia. *Frontiers in Psychiatry* 9. Available at: <https://doi.org/10.3389/fpsy.2018.00713>

Madeira C, Alheira FV, Calcia MA, Silva, Thuany CS, et al, 2018. Blood Levels of Glutamate and Glutamine in Recent Onset and Chronic Schizophrenia. *Frontiers in Psychiatry* 9:1–8. Available at: <https://doi.org/10.3389/fpsy.2018.00713>

- Mahmoud S, et al, 2019. Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release. *Cells* 8(2):184. Available at: <https://doi.org/10.3390/cells8020184>
- Malla A, Joobar R, Garcia A, 2015. “Mental illness is like any other medical illness”: a critical examination of the statement and its impact on patient care and society. *Journal of Psychiatry and Neuroscience* 40(3):147–150. Available at: <https://doi.org/10.1503/jpn.150099>
- Mart L, Brea J, Rico S, 2021. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments. *International Journal of Molecular Sciences* 22(18):9905. Available at: <https://doi.org/10.3390/ijms22189905>
- Mccutcheon A, Krystal JH, Howes OD, 2020. Dopamine and glutamate in schizophrenia: biology. *Symptoms and treatment* 15–33. Available at: <https://doi.org/10.1002/wps.20693>
- Mccutcheon RA, Keefe RSE, Mcguire PK, 2023. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. *Molecular Psychiatry* 1–17. Available at: <https://doi.org/doi.org/10.1038/s41380-023-01949-9>
- McCutcheon RA, Reis Marques T, Howes OD, 2020. Schizophrenia-An Overview. *JAMA Psychiatry* 77(2):201–210. Available at: <https://doi.org/10.1001/jamapsychiatry.2019.3360>
- Mei YY, Wu DC, Zhou N, 2018. Astrocytic regulation of glutamate transmission in schizophrenia. *Frontiers in Psychiatry* 9:1–10. Available at: <https://doi.org/10.3389/fpsy.2018.00544>
- Merritt K, et al, 2016. Nature of Glutamate Alterations in Schizophrenia. *JAMA Psychiatry* 73(7):665. Available at: <https://doi.org/10.1001/jamapsychiatry.2016.0442>
- Millan MJ, 2016. Cognitive dysfunction in psychiatric disorders: Characteristics, causes and the quest for improved therapy. *Nature Reviews Drug Discovery* 11(2):141–168

- Mithaiwala MN, et al, 2021. Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications. *Cells* 10(6):1548. Available at: <https://doi.org/10.3390/cells10061548>
- Moran P, et al, 2016. Gene  $\times$  Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models. *Neural Plasticity* 2016:1–23. Available at: <https://doi.org/10.1155/2016/2173748>
- Mowry B, et al, 2022. Anticholinergic burden and cognitive impairment in schizophrenia: An overlooked association. *Journal of Psychiatric Research* 154:122–130. Available at: <https://doi.org/10.1016/j.jpsychires.2022.08.014>
- Müller N, et al, 2019. The role of inflammation in schizophrenia. *Frontiers in Neuroscience* 13(665). Available at: <https://doi.org/10.3389/fnins.2015.00372>
- Nakahara T, et al, 2022. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of <sup>1</sup>H-magnetic resonance spectroscopy studies. *Molecular Psychiatry* 27(1):744–757. Available at: <https://doi.org/10.1038/s41380-021-01297-6>
- Namavar Y, et al, 2021. Psychiatric phenotypes associated with hyperprolinemia: A systematic review. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 186(5):289–317. Available at: <https://doi.org/10.1002/ajmg.b.32869>
- Natarajan SK, et al, 2012. Proline dehydrogenase is essential for proline protection against hydrogen peroxide-induced cell death, *Free Radical Biology and Medicine*. Available at: <https://doi.org/10.1016/j.freeradbiomed.2012.07.002>
- Niedzwiecki A, Goyal A, 2020. The kynurenine pathway in Alzheimers and other neurodegenerative diseases. *Journal of Neuroscience Research* 98(1):3–15
- Olsson SK, et al, 2019. Effects of pharmacological inhibition of kynurenine aminotransferase II on cognitive function in rodent models of schizophrenia. *Journal of Psychopharmacology* 33(7):857–867

- Oosterman JM, et al, 2021, Cognitive reserve relates to executive functioning in the old-old. *Aging Clinical and Experimental Research* 33(9):2587–2592. Available at: <https://doi.org/10.1007/s40520-020-01758-y>
- Orrico-Sánchez A, et al, 2020. Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. *BMC Psychiatry* 20(1)1–9. Available at: <https://doi.org/10.1186/s12888-020-02538-8>
- Parellada E, Gassó P, 2021. Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. *Translational Psychiatry* 11(1):271. Available at: <https://doi.org/10.1038/s41398-021-01385-9>
- Parkway P, 2020. General Variant Classification Assertion Criteria General Information
- Parrott JM, OConnor JC, Powder K, 2021. Environmental factors, kynurenine pathway, and their role in brain health. *Brain, Behavior, and Immunity* 93:104–113
- Pashler H, Johnston JC, Ruthruff E, 2017. Attention and performance. *Annual Review of Psychology* 68:43–68
- Patriarca EJ, et al, 2021. The Multifaceted Roles of Proline in Cell Behavior. *Frontiers in Cell and Developmental Biology* 9:1–28. Available at: <https://doi.org/10.3389/fcell.2021.728576>
- Patterson JC, McIntosh AM, Spencer MD, 2018. Neuroinflammatory gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia: a postmortem study. *Lancet Psychiatry* 5(1):22–31
- Pedraz-petrozzi B, et al, 2020. Effects of inflammation on the kynurenine pathway in schizophrenia — a systematic review. 1–18
- Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia, 2011. Konsensus Penatalaksanaan Gangguan Skizofrenia, Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia 94

- Perkovic MN, et al, 2017. Theranostic biomarkers for schizophrenia. *International Journal of Molecular Sciences* 18(4):1–38. Available at: <https://doi.org/10.3390/ijms18040733>
- Peters BD, et al, 2012. White Matter Development in Adolescence: Diffusion Tensor Imaging and Meta-Analytic Results. *Schizophrenia Bulletin* 38(6):1308–1317. Available at: <https://doi.org/10.1093/schbul/sbs054>.
- Plitman E, et al, 2017. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. *Schizophrenia Bulletin* 43(4):764–777. Available at: <https://doi.org/10.1093/schbul/sbw221>
- Plitman E, et al, 2021. Glutamate in schizophrenia: From pathophysiology to targets for novel antipsychotic treatments. *Neuroscience & Biobehavioral Reviews* 127:105–118. Available at: <https://doi.org/10.1016/j.neubiorev.2021.04.022>
- Posner MI, Rothbart MK, Tang YY, 2019. Developing self-regulation in early childhood. *Trends in Neurosciences* 42(6):395–405
- Qin X, Chen J, Zhou T, 2021. 22Q11.2 Deletion Syndrome and Schizophrenia. *Acta Biochimica et Biophysica Sinica* 52(11):1181–1190. Available at: <https://doi.org/10.1093/abbs/gmaa113>
- Rabin LA, Paolillo E, Barr WB, 2020. Stability in test-retest reliability of verbal fluency measures in cognitively healthy older adults. *Journal of the International Neuropsychological Society* 26(8):813–823
- Rees E, et al, 2020. Schizophrenia, glutamate, and the genomics of cognitive impairment. *Neuroscience & Biobehavioral Reviews* 118:426–439. Available at: <https://doi.org/10.1016/j.neubiorev.2020.08.003>
- Réus GZ, et al, 2018. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 81:55–63. Available at: <https://doi.org/10.1016/j.pnpbp.2017.10.009>

- Riglin L, et al, 2017. Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-based cohort study. *The Lancet Psychiatry* 4(1):57–62. Available at: [https://doi.org/10.1016/S2215-0366\(16\)30406-0](https://doi.org/10.1016/S2215-0366(16)30406-0)
- Roberts J, Stewart C, Kearney S, 2016. Management of the behavioural manifestations of Hunter syndrome. *British Journal of Nursing* 25(1):22–30. Available at: <https://doi.org/10.12968/bjon.2016.25.1.22>.
- Robertson IH, Garavan H, 2016. Vigilant attention. *Psychological Science* 10(2):82–88
- Robison AJ, Thakkar KN, Diwadkar VA, 2020. Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate, Biological Psychiatry: 87(3):204–214. Available at: <https://doi.org/10.1016/j.biopsych.2019.09.021>
- Sadock BJ, Sadock VA, 2017. Schizophrenia and Other Psychotic Disorders, in Kaplan and Sadocks Comprehensive Textbook of Psychiatry. 10th edn. Wolters Kluwer Health 3613–4004
- Sartorius N, 2018. Comorbidity of mental and physical disorders: a key problem for medicine in the 21st century. *Acta Psychiatrica Scandinavica* 137(5):369–370. Available at: <https://doi.org/10.1111/acps.12888>
- Sathyaikumar KV, et al, 2022. Tryptophan Challenge in Healthy Controls and People with Schizophrenia: Acute Effects on Plasma Levels of Kynurenine, Kynurenic Acid and 5-Hydroxyindoleacetic Acid. *Pharmaceuticals* 15(8)-1003. Available at: <https://doi.org/10.3390/ph15081003>
- Savitz J, 2020. The kynurenine pathway: a finger in every pie. *Molecular Psychiatry* 25(1):131–147. Available at: <https://doi.org/10.1038/s41380-019-0414-4>
- Schultz S, North S, Shields CG, 2007. Schizophrenia: A review, (July).
- Schwarcz R, et al, 2012. Kynurenines in the mammalian brain: when physiology meets pathology. *Nature Reviews Neuroscience* 13(7):465–477. Available at: <https://doi.org/10.1038/nrn3257>

- Schwieler L, et al, 2022. Neuroinflammation and kynurenine pathway in schizophrenia: a translational perspective. *Biological Psychiatry Global Open Science* 2(4):351–360. Available at: <https://doi.org/10.1016/j.bpsgos.2022.05.005>
- Sehgal SA, 2017. Pharmacoinformatics and molecular docking studies reveal potential novel Proline Dehydrogenase (PRODH) compounds for Schizophrenia inhibition. *Medicinal Chemistry Research* 26(2):314–326. Available at: <https://doi.org/10.1007/s00044-016-1752-2>
- Sharma A, Markon K, Clark LA, 2020. Toward a theory of executive function: A multidimensional framework for assessing executive function across domains. *Journal of Clinical and Experimental Neuropsychology* 42(1):23–25
- Siever LJ, Davis KL, 2004. The Pathophysiology of Schizophrenia Disorders: Perspectives From the Spectrum. *American Journal of Psychiatry* 161(3):398–413. Available at: <https://doi.org/10.1176/appi.ajp.161.3.398>
- Song J, et al, 2014. Peripheral glutamate levels in schizophrenia: Evidence from a meta-analysis. *Neuropsychobiology* 70(3):133–141. Available at: <https://doi.org/10.1159/000364828>
- Squire LR, Wixted JT, 2016, The cognitive neuroscience of human memory since H.M. *Annual Review of Neuroscience* 39:433–45
- Stępnicki P, Kondej M, Kaczor AA, 2018. Current concepts and treatments of schizophrenia. *Molecules* 23(8). Available at: <https://doi.org/10.3390/molecules23082087>
- Stilo SA, Murray RM, 2019. Non-Genetic Factors in Schizophrenia, *Current Psychiatry Reports* 21(100). Available at: <https://doi.org/https://doi.org/10.1007/s11920-019-1091-3>
- Stone TW, Darlington LG, 2016, The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders *British Journal of*

Pharmacology 173(6):1060–1077. Available at:  
<https://doi.org/10.1111/bph.12230>

Suhery D, Sari YO, Fitria N, 2023. Analisa Hubungan Biaya Total dan Lama Rawatan Penggunaan Risperidon dan Quetiapin pada Pasien Skizofrenia Paranoid di RS Jiwa Prof HB Saanin Padang. Jurnal Farmasi Higea 15(1):32. Available at: <https://doi.org/10.52689/higea.v15i1.51>

Suvisaari J, et al, 2018. Is It Possible to Predict the Future in First-Episode Psychosis?. Frontiers in Psychiatry 9. Available at:  
<https://doi.org/10.3389/fpsy.2018.00580>

Tanner JJ, 2019. Structural Biology of Proline Catabolic Enzymes. Antioxidants & Redox Signaling 30(4):650–673. Available at:  
<https://doi.org/10.1089/ars.2017.7374>

Trifu SC, Vlăduți A, Trifu AI, 2020. Genetic aspects in schizophrenia. Receptor theories. Metabolic theories. Romanian Journal of Morphology and Embryology 61(1):25–32. Available at:  
<https://doi.org/10.47162/RJME.61.1.03>

Uno Y, Coyle JT, 2019. Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences 73(5):204–215. Available at:  
<https://doi.org/10.1111/pcn.12823>

Utami MSS, et al, 2024. Adaptation of Rey Auditory Verbal Learning Test for Indonesia: Its Validity and Reliability. Acta Neuropsychologica 22:15–34

Valle R, 2020. Schizophrenia in ICD-11: Comparison of ICD-10 and DSM-5. Revista de Psiquiatria y Salud Mental 13(2):95–104. Available at:  
<https://doi.org/10.1016/j.rpsm.2020.01.001>

Vallianatou K, et al, 2021. Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaBrain Glutamate on Switching to Clozapine in Treatment

- Volkan K, 2020. Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment. *Journal of Health and Medical Sciences* 3(4). Available at: <https://doi.org/10.31014/aior.1994.03.04.143>
- Walter EE, et al, 2016. Genetic Consideration of Schizotypal Traits: A Review. *Frontiers in Psychology* 7. Available at: <https://doi.org/10.3389/fpsyg.2016.0176>
- Wang CY, et al, 2010. Cigarette Smoking in Patients with Schizophrenia in China: Prospective, Multicentre Study. *Australian & New Zealand Journal of Psychiatry* 44(5):456–462. Available at: <https://doi.org/10.3109/00048670903493348>
- Watson DR, et al, 2012. A voxel based morphometry study investigating brain structural changes in first episode psychosis. *Behavioural Brain Research* 227(1):91–99. Available at: <https://doi.org/10.1016/j.bbr.2011.10.034>
- Weinstein G, 2018. Neuroanatomical correlates of phonemic and semantic verbal fluency in older adults: A magnetic resonance imaging study. *Cognitive Neuroscience* 9(2):43–52
- WHO, 2022. Schizophrenia, WHO. Available at: <https://www.who.int/news-room/fact-sheets/detail/schizophrenia> (Accessed: 1 August 2022)
- Wonodi I, et al, 2018. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with cognitive function. *The Journal of Neuroscience* 38(2):740–752. Available at: <https://doi.org/10.1001/archgenpsychiatry.2011.71>
- Wonodi I, 2020. Peripheral kynurenine pathway markers in schizophrenia: A meta-analysis of human studies. *Schizophrenia Research* 220:248–257. Available at: <https://doi.org/10.1016/j.schres.2020.02.023>
- World Health Organization (WHO), 2022. ICD-11
- Wyse ATS, Netto CA, 2011. Behavioral and neurochemical effects of proline. *Metabolic Brain Disease* 26(3):159–172. Available at: <https://doi.org/10.1007/s11011-011-9246-x>

- Yao Y, Han W, 2022. Proline Metabolism in Neurological and Psychiatric Disorders. *Molecules and Cells*. 45(11):781–788. Available at: <https://doi.org/10.14348/molcells.2022.0115>
- Yelamanchi SD, et al, 2016, A pathway map of glutamate metabolism. *Journal of Cell Communication and Signaling* 69–75. Available at: <https://doi.org/10.1007/s12079-015-0315-5>
- Yoon SC, et al, 2016. Linkage and Association Analyses of Schizophrenia with Genetic Variations on Chromosome 22q11 in Koreans. 630–636
- Yue W, Huang H, Duan J, 2022. Potential diagnostic biomarkers for schizophrenia. *Medical Review* 2(4):385–416. Available at: <https://doi.org/10.1515/mr-2022-0009>
- Zelazo PD, 2020. Executive Function and Psychopathology: A Neurodevelopmental Perspective. *Annual Review of Clinical Psychology* 16(1):431–454. Available at: <https://doi.org/10.1146/annurev-clinpsy-072319-024242>
- Zhang J, 2019. Cognitive Functions of the Brain: Perception, Attention and Memory. Available at: <http://arxiv.org/abs/1907.02863>
- Zhang X, et al, 2021. Delayed recall and interference effects in schizophrenia: Evidence from verbal learning tasks. *Journal of Psychiatric Research* 135:217–224. Available at: <https://doi.org/10.1016/j.jpsychires.2021.07.019>
- Zhang Z, et al, 2019. Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 90:161–168. Available at: <https://doi.org/10.1016/j.pnpbp.2018.11.018>
- Zhou J, et al, 2022. Working memory deficits in children with schizophrenia and its mechanism, susceptibility genes, and improvement: A literature review. *Frontiers in Psychiatry* 13. Available at: <https://doi.org/10.3389/fpsy.2022.899344>

